| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 3, 2024 | BTAI Bioxcel Therapeutics, Inc. | Yocca Frank88 | Chief Scientific Officer | Sell | 7,175 | $0.55 | $3,946.25 | -20.2% | -28.7% | -71.3% | |
| Oct 3, 2024 | BTAI Bioxcel Therapeutics, Inc. | O'Neill Vincent86 | See Remarks | Sell | 5,556 | $0.55 | $3,055.80 | -22.1% | -28.7% | -71.3% | |
| Oct 3, 2024 | BTAI Bioxcel Therapeutics, Inc. | Rodriguez Javier87 | See Remarks | Sell | 6,863 | $0.55 | $3,774.65 | -22.4% | -28.7% | -71.3% | |
| Oct 2, 2024 | HIMS Hims & Hers Health, Inc. | Okupe Oluyemi55 | Chief Financial Officer | Sell | 11,581 | $18.92 | $219,084.44 | -1.8% | +27.6% | +205.4% | |
| Oct 1, 2024 | RMTI Rockwell Medical, Inc. | Chole Timothy73 | SVP, Chief Commercial Officer | Sell | 1,001 | $3.69 | $3,688.89 | -1.8% | -44.3% | -67.7% | |
| Oct 1, 2024 | RMTI Rockwell Medical, Inc. | Strobeck Mark72 | President And CEO | Sell | 2,163 | $3.69 | $7,971.09 | -1.4% | -44.3% | -67.7% | |
| Oct 1, 2024 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 2,339 | $18.50 | $43,271.50 | -1.3% | +30.3% | +191.6% | |
| Oct 1, 2024 | HIMS Hims & Hers Health, Inc. | Dudum Andrew47 | Chief Executive Officer | Sell | 333,332 | $18.19 | $6,064,556.30 | -27.5% | +30.3% | +191.6% | |
| Sep 30, 2024 | UTHR United Therapeutics Corp | Edgemond James | CFO And Treasurer | Sell | 7,792 | $358.62 | $2,794,367.04 | -28.0% | -0.2% | +17.0% | |
| Sep 30, 2024 | CGC Canopy Growth Corp | Kruh Willy74 | Director | Sell | 1,995 | $4.95 | $9,875.25 | -13.1% | -43.2% | -69.7% | |
| Sep 30, 2024 | CGC Canopy Growth Corp | Lazzarato David Angelo75 | Director | Sell | 2,993 | $4.95 | $14,815.35 | -9.4% | -43.2% | -69.7% | |
| Sep 30, 2024 | AMLX Amylyx Pharmaceuticals, Inc. | Klee Justin B.60 | Co-chief Executive Officer | Sell | 18,589 | $3.20 | $59,429.03 | -0.6% | +18.5% | +319.4% | |
| Sep 30, 2024 | CGC Canopy Growth Corp | Yanofsky Theresa75 | Director | Sell | 1,987 | $4.95 | $9,835.65 | -7.6% | -43.2% | -69.7% | |
| Sep 30, 2024 | AMLX Amylyx Pharmaceuticals, Inc. | Bedrosian Camille L64 | Chief Medical Officer | Sell | 11,442 | $3.20 | $36,559.48 | -7.4% | +18.5% | +319.4% | |
| Sep 30, 2024 | AMLX Amylyx Pharmaceuticals, Inc. | Mazzariello Gina53 | Chief Legal Officer | Sell | 8,709 | $3.20 | $27,840.06 | -5.7% | +18.5% | +319.4% | |
| Sep 30, 2024 | AMLX Amylyx Pharmaceuticals, Inc. | Cohen Joshua B60 | Co-chief Executive Officer | Sell | 18,589 | $3.20 | $59,414.16 | -0.6% | +18.5% | +319.4% | |
| Sep 30, 2024 | CGC Canopy Growth Corp | Mongeau Luc79 | Director | Sell | 1,995 | $4.95 | $9,875.25 | -13.1% | -43.2% | -69.7% | |
| Sep 30, 2024 | BIOE Bio Essence Corp | Yan Yin | Chief Executive Officer | Sell | 92,190 | $1.16 | $106,814.50 | -0.2% | - | - | |
| Sep 27, 2024 | BIOA Bioage Labs, Inc. | Barton Shane | Principal Accounting Officer | Buy | 2,632 | $18.00 | $47,376.00 | New | -72.0% | -74.2% | |
| Sep 27, 2024 | BIOA Bioage Labs, Inc. | Cormorant Asset Management, LP49 | - | Buy | 450,000 | $18.00 | $8,100,000.00 | +38.2% | -72.0% | -74.2% | |
| Sep 27, 2024 | BIOA Bioage Labs, Inc. | Pande Vijay Satyanand | Director | Buy | 900,000 | $18.00 | $16,200,000.00 | New | -72.0% | -74.2% | |
| Sep 27, 2024 | GSK Gsk Plc | Gsk Plc | 10% Owner | Buy | 2,791,930 | $8.00 | $22,335,440.00 | +20.0% | -16.2% | -2.1% | |
| Sep 27, 2024 | BIOA Bioage Labs, Inc. | Enright Patrick G74 | Director | Buy | 400,000 | $18.00 | $7,200,000.00 | +30.5% | -72.0% | -74.2% | |
| Sep 27, 2024 | BIOA Bioage Labs, Inc. | Healy James | Director | Buy | 666,665 | $18.00 | $11,999,970.00 | +40.7% | -72.0% | -74.2% | |
| Sep 23, 2024 | KNSA Kiniksa Pharmaceuticals International, Plc | Tessari Eben | Chief Operating Officer | Sell | 17,500 | $24.99 | $437,325.00 | -13.0% | -17.7% | +47.6% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.